Clinical trials indicate a 27% decrease in HHF and a 15% decrease in CV mortality, which is a statistically significant reduction [51,52]. The findings highlight the effectiveness of SGLT2 inhibitors in reducing acute HF incidents and improving long-term CV health in patients with T2DM [57]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.